Cancer

February 24, 2019

Combinatorial therapy targeting PD-L1 pathway enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Metformin, Navitoclax/ABT-263, Dasatinib and 2-Deoxy-d-glucose (MNDDG) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 25/February/2019, 12.17 pm

Combinatorial therapy targeting PD-L1 pathway enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Metformin, Navitoclax/ABT-263, Dasatinib and 2-Deoxy-d-glucose (MNDDG) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 25/February/2019, 12.17 pm https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-Dasatinib-and-2deoxydglucose-MNDDG-inhibits-the-expression-of-EGFR-and-Bcl2xl.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-Dasatinib-and-2deoxydglucose-MNDDG-inhibits-the-expression-of-EGFR-and-Bcl2xl.jpg February 24, 2019 February 24, 2019

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center, David Geffen UCLA…

February 22, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 22/February/2019, 10.12 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing a pharmacological formulation encompassing Metformin, Navitoclax/ABT-263, & Dasatinib (MND) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 22/February/2019, 10.12 pm https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-and-Dasatinib-MND-functions-as-an-antitumor-metastasis-agent1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-pharmaceutical-mixture-encompassing-Metformin-Navitoclax-and-Dasatinib-MND-functions-as-an-antitumor-metastasis-agent1.jpg February 22, 2019 February 22, 2019

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in…

February 22, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Fenofibrate and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as KIBRA, PTPN14, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 22/February/2019, 9.40 pm

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Fenofibrate and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as KIBRA, PTPN14, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 22/February/2019, 9.40 pm https://genomediscovery.org/wp-content/uploads/2019/02/Fenofibrate-increaes-the-exp.-of-PTN14-KIBRA-and-others-and-attenuates-tumor-progression.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/Fenofibrate-increaes-the-exp.-of-PTN14-KIBRA-and-others-and-attenuates-tumor-progression.jpg2_.jpg February 22, 2019 February 22, 2019

February 19, 2019

Combinatorial therapy for metastasis: A pharmacological mixture Simvastatin and Navitoclax/ABT-263 (SAN) inhibits the expression of IL-6/8, decreases the expression of downstream molecules WASF3 and Arp2/3, suppresses tumor cell migration, reduces metastasis and prolongs survival via up regulation of its target gene, 20/February/2019, 12.54 am

Combinatorial therapy for metastasis: A pharmacological mixture Simvastatin and Navitoclax/ABT-263 (SAN) inhibits the expression of IL-6/8, decreases the expression of downstream molecules WASF3 and Arp2/3, suppresses tumor cell migration, reduces metastasis and prolongs survival via up regulation of its target gene, 20/February/2019, 12.54 am https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-Simvastatin-and-Navitoclax-SAN-inhibits-WASF-and-ARP2.3-and-attenuates-cancer-metastasis.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-Simvastatin-and-Navitoclax-SAN-inhibits-WASF-and-ARP2.3-and-attenuates-cancer-metastasis.jpg February 19, 2019 February 19, 2019

Introduction: What they say: A study from Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, Maryland 21218, USA; Johns Hopkins Physical Sciences-Oncology Center, The Johns Hopkins University, Baltimore, Maryland…

February 19, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Paclitaxel (PTX) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 20/February/2019, `12.42 am

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Paclitaxel (PTX) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 20/February/2019, `12.42 am https://genomediscovery.org/wp-content/uploads/2019/02/Paclitaxel-fns-as-an-antimetasis-agent-through-induciton-of-TPM1-TIMP3-and-others-2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/Paclitaxel-fns-as-an-antimetasis-agent-through-induciton-of-TPM1-TIMP3-and-others-2.jpg February 19, 2019 February 19, 2019

February 19, 2019

Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing Fenofibrate and Paclitaxel(PTX) (FAP) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers, via up-regulation of its target gene, 20/February/2019, 12.23 am

Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing Fenofibrate and Paclitaxel(PTX) (FAP) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers, via up-regulation of its target gene, 20/February/2019, 12.23 am https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-fenofibrate-and-paclitaxel-aridia-inhibits-expression-and-stalls-the-progression-of-cancer.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-fenofibrate-and-paclitaxel-aridia-inhibits-expression-and-stalls-the-progression-of-cancer.jpg February 19, 2019 February 19, 2019

Introduction: What they say: A study from Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA shows that “ARID1A-mutated ovarian cancers depend on HDAC6 activity” This study…

Popular Post